Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04866017
Title Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors BeiGene
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

BGBA1217 + Tislelizumab

Tislelizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST